CN110218791A - Spz1的用途及其抑制剂的用途、药物组合物和药物筛选方法 - Google Patents
Spz1的用途及其抑制剂的用途、药物组合物和药物筛选方法 Download PDFInfo
- Publication number
- CN110218791A CN110218791A CN201910404910.9A CN201910404910A CN110218791A CN 110218791 A CN110218791 A CN 110218791A CN 201910404910 A CN201910404910 A CN 201910404910A CN 110218791 A CN110218791 A CN 110218791A
- Authority
- CN
- China
- Prior art keywords
- spz1
- drug
- intestinal cancer
- colon
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910404910.9A CN110218791B (zh) | 2019-05-15 | 2019-05-15 | Spz1的用途及其抑制剂的用途、药物组合物和药物筛选方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910404910.9A CN110218791B (zh) | 2019-05-15 | 2019-05-15 | Spz1的用途及其抑制剂的用途、药物组合物和药物筛选方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110218791A true CN110218791A (zh) | 2019-09-10 |
CN110218791B CN110218791B (zh) | 2023-09-01 |
Family
ID=67821287
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910404910.9A Active CN110218791B (zh) | 2019-05-15 | 2019-05-15 | Spz1的用途及其抑制剂的用途、药物组合物和药物筛选方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110218791B (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070141672A1 (en) * | 2005-11-03 | 2007-06-21 | Jumi Shin | Minimalist bZIP Proteins and uses thereof |
CN103146689A (zh) * | 2013-02-04 | 2013-06-12 | 四川大学 | 短发夹shRNA及其在制备治疗结直肠癌的药物中的应用 |
CN103656642A (zh) * | 2012-08-31 | 2014-03-26 | 中国科学院上海生命科学研究院 | 预防和治疗结直肠癌的方法和试剂 |
CN106727461A (zh) * | 2016-12-30 | 2017-05-31 | 上海市肺科医院 | 一种kdm1a小分子抑制剂在抑制肿瘤细胞生长和转移中的应用 |
CN108434455A (zh) * | 2018-04-23 | 2018-08-24 | 中山大学肿瘤防治中心 | Mthfd2特异性抑制剂在防治结直肠癌方面的应用 |
-
2019
- 2019-05-15 CN CN201910404910.9A patent/CN110218791B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070141672A1 (en) * | 2005-11-03 | 2007-06-21 | Jumi Shin | Minimalist bZIP Proteins and uses thereof |
CN103656642A (zh) * | 2012-08-31 | 2014-03-26 | 中国科学院上海生命科学研究院 | 预防和治疗结直肠癌的方法和试剂 |
CN103146689A (zh) * | 2013-02-04 | 2013-06-12 | 四川大学 | 短发夹shRNA及其在制备治疗结直肠癌的药物中的应用 |
CN106727461A (zh) * | 2016-12-30 | 2017-05-31 | 上海市肺科医院 | 一种kdm1a小分子抑制剂在抑制肿瘤细胞生长和转移中的应用 |
CN108434455A (zh) * | 2018-04-23 | 2018-08-24 | 中山大学肿瘤防治中心 | Mthfd2特异性抑制剂在防治结直肠癌方面的应用 |
Non-Patent Citations (6)
Title |
---|
L-T WANG等: "Transcription factor SPZ1 promotes TWIST-mediated epithelial–mesenchymal transition and oncogenesis in human liver cancer", 《ONCOGENE》 * |
L-T WANG等: "Transcription factor SPZ1 promotes TWIST-mediated epithelial–mesenchymal transition and oncogenesis in human liver cancer", 《ONCOGENE》, vol. 36, no. 31, 31 August 2017 (2017-08-31), pages 9 * |
XIAOYU LIU等: "SPZ1 is critical for chemoresistance and aggressiveness in drug-resistant breast cancer cells", 《BIOCHEMICAL PHARMACOLOGY》 * |
XIAOYU LIU等: "SPZ1 is critical for chemoresistance and aggressiveness in drug-resistant breast cancer cells", 《BIOCHEMICAL PHARMACOLOGY》, 31 October 2018 (2018-10-31), pages 46 * |
张灵敏等: "Spz1和Rap1b在食管鳞癌中的表达及临床意义", 《山西医科大学学报》 * |
张灵敏等: "Spz1和Rap1b在食管鳞癌中的表达及临床意义", 《山西医科大学学报》, vol. 48, no. 5, 23 May 2017 (2017-05-23), pages 471 - 474 * |
Also Published As
Publication number | Publication date |
---|---|
CN110218791B (zh) | 2023-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Jurcak et al. | Axon guidance molecules promote perineural invasion and metastasis of orthotopic pancreatic tumors in mice | |
Qi et al. | Hesperidin inhibits synovial cell inflammation and macrophage polarization through suppression of the PI3K/AKT pathway in complete Freund's adjuvant-induced arthritis in mice | |
Bates et al. | Tumor necrosis factor-α stimulates the epithelial-to-mesenchymal transition of human colonic organoids | |
Duah et al. | Cysteinyl leukotriene 2 receptor promotes endothelial permeability, tumor angiogenesis, and metastasis | |
Jiang et al. | Galectin-1 gene silencing inhibits the activation and proliferation but induces the apoptosis of hepatic stellate cells from mice with liver fibrosis | |
Tang et al. | Upregulation of the δ opioid receptor in liver cancer promotes liver cancer progression both in vitro and in vivo Retraction in/10.3892/ijo. 2023.5504 | |
Shao et al. | The tumor suppressor gene RBM5 inhibits lung adenocarcinoma cell growth and induces apoptosis | |
Zhong et al. | A traditional Chinese medicine herb mixture Qingjie Fuzheng granules inhibits hepatocellular carcinoma cells growth by inducing apoptosis | |
CN107419004A (zh) | lncRNA‑RP11‑290F20.3及其小干扰RNA的应用 | |
Cheng et al. | Antitumor effect of saikosaponin A on human neuroblastoma cells | |
Yang et al. | Xanthatin selectively targets retinoblastoma by inhibiting the PLK1-mediated cell cycle | |
Wang et al. | Fucoxanthin prevents breast cancer metastasis by interrupting circulating tumor cells adhesion and transendothelial migration | |
Zhang | Abrine Elicits Liver Carcinoma Immunity and Enhances Antitumor Efficacy of Immune Checkpoint Blockade by Modulating PD‐L1 Signaling | |
CN104758292A (zh) | Pd-0332991在制备防治耐药肿瘤药物的用途 | |
Jia et al. | Antitumor activity of tenacissoside H on esophageal cancer through arresting cell cycle and regulating PI3K/Akt‐NF‐κB transduction cascade | |
Tan et al. | Erchen Plus Huiyanzhuyu Decoction Inhibits the Growth of Laryngeal Carcinoma in a Mouse Model of Phlegm‐Coagulation‐Blood‐Stasis Syndrome via the STAT3/Cyclin D1 Pathway | |
Zhu et al. | EIF3B promotes cancer progression in pancreatic cancer | |
CN107739759A (zh) | 一种rdh10基因在脑胶质瘤疾病中的应用 | |
Liu | Curcumol targeting PAX8 inhibits ovarian cancer cell migration and invasion and increases chemotherapy sensitivity of niraparib | |
Li et al. | [Retracted] Analysis of Molecular Mechanism of YiqiChutan Formula Regulating DLL4‐Notch Signaling to Inhibit Angiogenesis in Lung Cancer | |
Zhou et al. | miR-143-3p shuttled by M2 macrophage-derived extracellular vesicles induces progression of colorectal cancer through a ZC3H12A/C/EBPβ axis-dependent mechanism | |
CN110218791A (zh) | Spz1的用途及其抑制剂的用途、药物组合物和药物筛选方法 | |
CN109106715B (zh) | 8-羟基喹啉类药物或其盐在制备用于治疗与brd4相关的疾病的药物中的应用 | |
Gazdar et al. | Targeted therapies for killing tumor cells | |
CN107739758A (zh) | 一种RDH10基因用于制备TWEAK‑NF‑κB信号通路阻断剂的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20200820 Address after: Shenzhen ENT Hospital, no.3004 Longgang section, Longgang Avenue, Longgang District, Shenzhen City, Guangdong Province Applicant after: SHENZHEN CITY LONGGANG DISTRICT OTOLARYNGOLOGY Hospital Address before: 518172 Longgang section, Longgang Avenue, Longgang District, Shenzhen, Guangdong Province, No. 3004 (next to Jixiang station line 3 line), Shenzhen otorhinolaryngology Institute Applicant before: Zhang Peng Applicant before: SHENZHEN CITY LONGGANG DISTRICT OTOLARYNGOLOGY Hospital |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant |